Great Lakes Pharmaceuticals, Inc. is a clinical stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters. Their first product, B-Lock™, is an anticoagulant catheter lock solution that works against the bacterial and fungal microorganisms known to form biofilm structures in catheters. Biofilm-related infections are the 8th leading cause of death in the United States. Headquartered in Concord, OH with offices in San Diego, CA, Great Lakes Pharmaceuticals assembled teams of experienced and distinguished scientists, clinicians, and managers to assure a smooth development as well as the commercialization of innovative, effective treatments of microbial infections in clinical and outpatient settings.
Great Lakes Pharmaceuticals has received investment from the North Coast Angel Fund and the Jumpstart Evergreen, Next, and Focus funds.